Immunome (IMNM) EBITDA (2019 - 2026)

Immunome's EBITDA history runs 8 years deep, the most recent figure standing at -$59.3 million for Q1 2026.

• Quarterly EBITDA fell 32.92% year-over-year to -$59.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$238.8 million (down 9.48% YoY) and the FY2025 annual result came in at -$224.1 million, up 26.71% from the prior year.
• EBITDA was -$59.3 million for Q1 2026 at Immunome, up from -$72.9 million in the prior quarter.
• Across five years, EBITDA topped out at -$4.5 million in Q1 2023 and bottomed at -$132.3 million in Q1 2024.
• A 5-year average of -$43.3 million and a median of -$44.6 million in 2025 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2024 — EBITDA plunged 2859.05% — and 2025, when it soared 66.26%.
• Immunome's EBITDA stood at -$7.8 million in 2022, then slumped by 1115.53% to -$94.7 million in 2023, then grew by 12.34% to -$83.0 million in 2024, then grew by 12.18% to -$72.9 million in 2025, then increased by 18.57% to -$59.3 million in 2026.
• Business Quant data shows IMNM's EBITDA at -$59.3 million in Q1 2026, -$72.9 million in Q4 2025, and -$60.1 million in Q3 2025.